NASDAQ NMS - GLOBAL MARKET · TECX
-0.77% · -$0.2100 · Vol 330.6K
Market closed · last close 4:00 PM ET · price as of 16:06:58 ET
Tectonic Therapeutic Inc

Tectonic Therapeutic Inc

Biotechnology
$27.00
Card
Relationship Map

Follow $TECX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $TECX by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
TECX
Tectonic Therapeutic Inc
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 4 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is TECX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading TECX catalysts
About Tectonic Therapeutic Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2024
Employees
60
Country
US

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$27.30
Day high
$27.59
Day low
$26.38
Previous close
$27.21
52W high
$37.93
-28.82% from high
52W low
$14.71
53% of range
Market cap
$527.8M
EPS
$-4.6100
Beta
0.64
Shares out
19.5M
Volume
330.6K
1.44× rel vol
Avg volume
229.6K
VWAP
$27.02
Price history computed in-house
1W
-7.06%
1M
-25.10%
3M
-10.06%
1Y
+80.24%
YTD
+29.43%
SMA 50 $31.92 · below
SMA 200 $27.76 · below
52W position 53%

TECX overview

Loading financial statements
Loading TECX Form 4 filings
Public disclosures

Congress activity in TECX

No receipt-qualified Congressional disclosure is present for TECX in the cached public ledger.

Federal contracts

TECX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for TECX in this window.
Lobbying spend

TECX lobbying filings, year to date.

Registered lobbying filings matched to Tectonic Therapeutic Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for TECX in this window.
Loading news for TECX
Analyst ratings
Sovereign unlock shows live analyst consensus for TECX.
Options
Sovereign unlock shows live options positioning for TECX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.